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Background: Ulinastatin has anti-inflammatory properties and protects organs from ischemia/reperfusion-
induced injury. The aim of this study was to investigate whether ulinastatin provides a protective effect on a 
regional myocardial ischemia/reperfusion injury in an in vivo rat heart model and to determine whether the anti-
inflammatory response is related to its myocardial protective effect. 
Methods: Rats were randomized to two groups. One group is received ulinastatin (50,000 U/kg or 100,000 U/kg) 
diluted in normal saline and the other group is received normal saline, which was administered intraperitoneally 
30 min before the ischemic insult. Reperfusion after 30 min of ischemia of the left coronary artery territory was 
applied. Hemodynamic measurements were recorded serially during 6 h after reperfusion. After the 6 h reperfusion, 
myocardial infarct size, cardiac enzymes, myeloperoxidase activity, and inflammatory cytokine levels were compared 
between the ulinastatin treated and untreated groups. 
Results: Ulinastatin improved cardiac function and reduced infarct size after regional ischemia/reperfusion injury. 
Ulinastatin significantly attenuated tumor necrosis factor-α expression and reduced myeloperoxidase activity. 
Conclusions: Ulinastatin showed a myocardial protective effect after regional ischemia/reperfusion injury in an 
in vivo rat heart model. This protective effect of ulinastatin might be related in part to ulinastatin’s ability to inhibit 
myeloperoxidase activity and decrease expression of tumor necrosis factor-α. (Korean J Anesthesiol 2011; 61: 499-505)
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Introduction
Since protease activation is one of known mechanisms for 
deve  lo  ping ischemic injury, inhibiting this protease activation 
has been proposed to attenuate post-ischemic injury [1-4]. 
Proteases, which are secreted from activated neutrophils during 
acute inflammatory phase, degrade the extracellular matrix and 
lead to tissue injury. While several protease inhibitors showed 
a myocardial protective effect in ischemia/reperfusion (I/R) 
injury models [5-7], ulinastatin, a protease inhibitor derived 
from human urine, also showed organ protective effect against 
I/R injury in the brain [8,9], liver [10,11], kidney [12], lung 
[13], and heart [6,7]. Previous investigations have showed that 
ulinastatin reduces the release of elastase from neutrophils and 
inhibits the accumulation of neutrophils in various I/R injury 
models [5,8,10,13] meaning that ulinastatin’s protective effect is 
due to its anti-inflammatory response. 
In this study, the effect of ulinastatin on several physiological 
and biochemical variables in an in vivo rat heart model of 
regional I/R injury was performed to determine whether 
ulinastatin’s myocardial protective effects were due to an anti-
inflammatory response. 
Materials and Methods  
Animal preparation 
Male Sprague-Dawley rats (Sam Tako Inc., Osan, South Korea) 
weighing between 220 and 250 g were used for this study. All 
animals were maintained in accordance with the Guidelines for 
the Care and Use of Laboratory Animals published by the US 
National Institutes of Health in 1996. The protocol was approved 
by the Animal Research Committee.
Animal preparation and surgery were performed as pre-
viously described [14]. Animals received general anesthesia with 
an intramuscular injection of 15 mg/kg of tiletamine/zolazepam 
(Zoletil50
Ⓡ, Virbac Lab., Carros, France) and 8 mg/kg of xylazine 
(Rompun
Ⓡ, Bayer, Seoul, South Korea). Additionally, 15 mg/kg 
of tiletamine/zolazepam and 8 mg/kg of xylazine was injected 
to maintain the level of anesthesia after 3 h reperfusion. If the 
tail moved (i.e. a sign of awakening), an additional 7.5 mg/kg 
of tiletamine/zolazepam and 4 mg/kg of xylazine was injected 
to maintain the level of anesthesia. The trachea was intubated, 
and then lungs were mechanically ventilated (tidal volume, 8 
ml/kg; respiratory rate, 80 strokes/min) with ambient air using a 
volume-controlled rodent ventilator (Harvard Rodent Ventilator 
Model 607, Harvard, Holliston, MA, USA). The arterial blood pH 
and gases were maintained within normal physiological limits 
(pH, 7.35-7.45; PaCO2, 30-40 mmHg; PaO2, 60-100 mmHg). 
A paramedian sternotomy was performed, and the pericar-
dium was opened to expose the heart. For the I/R experiments, 
a 4-0 black silk was passed around the left coronary artery 
(LCA) territory to induce regional myocardial ischemia. The 
coronary artery was occluded by pulling a snare through a 
small vinyl chloride tube and clamping it with a mosquito 
haemostat. Reperfusion was achieved by releasing the clamp. 
Myocardial ischemia was confirmed by the appearance of 
regional epicardial cyanosis over the myocardial surface and 
by arrhythmia. After 30 min of ischemia, the myocardium was 
reperfused by loosening the snare, which was maintained for 
6 h of reperfusion. Successful reperfusion was confirmed by 
the disappearance of epicardial cyanosis and the production of 
epicardial hyperaemia and arrhythmia after releasing the snare. 
Body temperature was monitored with a rectal thermometer 
(Sirecust 1260, Siemens Medical Electronics, MA, USA) and 
maintained at 36-38
oC with an electrical heating pad.
Experimental protocols 
The animals were divided randomly into two sets of experi-
ments. In the first set of experiments, animals were divided into 
three groups as follows: (1) I/R + Normal Saline (NS) group - 
rats in which 1 ml NS was administered intraperitoneally 30 min 
before the ischemic insult (n = 10), (2) I/R + U50 group - rats in 
which 50,000 U/kg ulinastatin (Ulistin
Ⓡ, Hanlim, Seoul, South 
Korea) diluted with NS was administered intraperitoneally 30 
min before the ischemic insult (n = 10), and (3) I/R + U100 
group - rats in which 100,000 U/kg ulinastatin diluted with NS 
was administered intraperitoneally 30 min before the ischemic 
insult (n = 10). Rats underwent a 30 min ischemia followed by 
reperfusion of the LCA territory. Hemodynamic measurements 
were recorded serially (30 min, 1 h, 1 h 30 min, 2 h, 6 h) 
during the 6 h of reperfusion, and myocardial infarct size was 
measured. 
In the second set of experiments, animals were divided into 
five groups as follows: (1) sham + NS group - rats in which 1 
ml NS was administered intraperitoneally 30 min before the 
sham operation (n = 6), (2) sham + U100 group - rats in which 
100,000 U/kg ulinastatin diluted with NS was administered 
intraperitoneally 30 min before the sham operation (n = 6), 
(3) I/R + NS group - rats in which 1 ml NS was administered 
intraperitoneally 30 min before the ischemic insult (n = 6), (4) 
I/R + U50 group - rats in which 50,000 U/kg ulinastatin diluted 
with NS was administered intraperitoneally 30 min before 
the ischemic insult (n = 6), and (5) I/R + U100 group - rats in 
which 100,000 U/kg ulinastatin diluted by NS was administered 
intraperitoneally 30 min before the ischemic insult (n = 6). All 
animals were exposed to 30 min ischemia followed by 6 h of 
reperfusion. The sham group had paramedian sternotomy and 
pericardiotomy performed without the LCA occlusion. The 501 www.ekja.org
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thoracic cavity was opened to expose the heart for sampling of 3 
ml blood from the right ventricle. Blood samples were collected 
in heparin containing tubes or conical tubes to measure cardiac 
troponin-I (cTnI), creatine kinase (CK) concentration, tumor 
necrosis factor (TNF)-α, and myeloperoxidase (MPO) activity. 
The entire sample was centrifuged, and serum and/or plasma 
were collected and frozen at -70
oC until analysed. 
Measurement of hemodynamic variables and myocar  dial 
contractility
The right common carotid artery was cannulated with a 
2-Fr Millar catheter (Model SPR-407, Millar Instruments Inc., 
Houston, TX, USA) and advanced into the left ventricle (LV) 
to measure baseline hemodynamic function (heart rate [HR], 
left ventricular end diastolic pressure [LVEDP], the maximum 
rate of intraventricular pressure increase [+dP/dtmax], and the 
maximum rate of intraventricular pressure decrease [-dP/
dtmax]). Hemodynamic measurements were recorded serially (30 
min, 1 h, 1 h 30 min, 2 h, 6 h) during the 6 h of reperfusion.
Area at risk and infarct size determination
After cardiac function analysis, the LCA was occluded again 
and 2 ml of 1% Evans blue dye was injected into the pulmonary 
artery to facilitate area at risk (AAR) determination as described 
in a previous report [14]. The perfused myocardium was stained 
with Evans blue dye, whereas the occluded vascular bed was 
not. The atrium, right ventricle, and major vessels were removed 
from the heart, and the AAR was separated from the non-
ischemic area. The AAR was cut into small pieces and incubated 
in 2% 2,3,5-triphenyltetrazolium chloride (TTC) at 37
oC for 20 
min. The non-infarcted myocardium stained a deep red color 
with TTC, and the infarcted area (IA) remained pale yellow. The 
sections were fixed for 24 h in 2% formalin, and the LV, AAR, and 
IA weights were determined. The AAR and IA were expressed as 
a percentage of the LV and AAR weights, respectively. 
cTnI and CK measurements
Serum levels of cTnI were determined by an enzyme linked 
immunosorbent assay (ELISA) kit from Life Diagnostics (cat. 
no. 2010-2-HS, Life Diagnostics Inc., Wester Chester, PA, USA) 
as described previously [14]. The cTnI activity was detected 
by spectrophotometry (Infinite
Ⓡ F200, Tecan Group Ltd., 
Männedorf, Switzerland) at 460 nm. Serum levels of CK were 
determined by EnzyChrom
TM creatine kinase assay kit (ECPK-
100, BioAssay Systems, CA, USA). CK activities were detected by 
colorimetric determination at 340 nm. 
Measurement of MPO and TNF-α activities 
Plasma level of MPO were determined by rat MPO ELISA test 
kit (Hbt HK 105, Hycult biotechnology b.v., Uden, Netherlands) 
according to the manufacturer as described previously 
[15]. MPO activities were detected to determine neutrophil 
accumulation by spectrophotometry (Infinite
Ⓡ F200, Tecan 
Group Ltd., Männedorf, Switzerland) at 460 nm after reaction 
of the plasma sample at MPO antibody-coated plate. Plasma 
concentrations of immunoreactive TNF-α were determined 
with an ELISA kit (RAT00, R&D Systems inc., Minneapolis, MN, 
USA) according to the manufacturer’s protocol as described 
previously [15]. This assay employs the quantitative sandwich 
enzyme immunoassay technique. Plasma was reacted with 
the assay reagents in the TNF-α kit and analyzed by spectro-
photometry (Infinite
Ⓡ F200, Tecan Group Ltd., Männedorf, 
Switzerland) at an absorbance of 460 nm. 
Statistical analysis 
All values are expressed as the means ± SD. All statistical 
analyses were performed using SPSS software (ver. 12.0 for 
Windows, SPSS Inc., Chicago, IL, USA). The differences between 
groups were evaluated using a Friedman one-way analysis 
of variance and a Tukey’s multiple comparison post	hoc test. 
Statistical significance was defined as P < 0.05. 
Results 
Hemodynamic function following I/R injury
The hemodynamic measurements recorded serially during 
the 6 h after reperfusion revealed substantial LV dysfunction as 
demonstrated by decreased ±dP/dtmax after I/R injury in the I/R + 
NS group compared to the basal hemodynamic function (Fig. 1). The 
LVEDP in the I/R + U100 group (12 ± 2 mmHg, P = 0.012) showed 
significant difference compared to the I/R + NS group (15 ± 2 
mmHg ) after 6 h of reperfusion. The ±dP/dtmax in the I/R + U100 
group (+dP/dtmax: +3,088 ± 362 mmHg; P < 0.001, -dP/dtmax: 
-2,157 ± 290 mmHg; P = 0.011) showed significant difference 
compared to the I/R + NS group (+dP/dtmax: +3,972 ± 227 mmHg/
sec, -dP/dtmax: -3,412 ± 248 mmHg) after 6 h of reperfusion. The 
HR was not significant difference between the groups. 
Myocardial infarct size
The AAR/LV induced by occluding the LCA territory was 
not significantlt different between the three groups. The IA/
AAR in the I/R + NS group (49 ± 7 %) was significantly different 
compared to the I/R + U50 (40 ± 7 %, P = 0.016) and I/R + U100 502 www.ekja.org
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groups (33 ± 7 %, P < 0.001) (Fig. 2). 
Serum CK and cTnI levels 
I/R induced a significant increase in the serum level of CK 
after 6 h reperfusion. The elevation of serum CK concentration 
in the I/R + NS group (200 ± 40 U/L) was significantlt inhibited 
in the I/R + U50 (149 ± 45 U/L, P = 0.012) and I/R + U100 (114 
± 35 U/L, P < 0.001) groups after regional I/R injury (Fig. 3). I/
R induced a significant increase in serum levels of cTnI after 6 
h reperfusion. The elevation of serum cTnI concentration in the 
I/R + NS group (20 ± 4 ng/ml) were significantly higher than in 
the I/R + U50 (16 ± 3 ng/ml, P = 0.043) and I/R + U100 (14 ± 4 
ng/ml, P = 0.012) groups after regional I/R injury (Fig. 4). 
Plasma MPO and TNF-α activity
I/R induced a significant increase in the plasma level of 
MPO after 6 h reperfusion. The elevation of plasma MPO 
concentration in the I/R + NS group (3,760 ± 60 ng/ml) were 
significantly higher than the I/R + U50 (3,572 ± 84 ng/ml, P = 
0.041) and I/R + U100 (2,848 ± 120 ng/ml, P < 0.001) groups 
after regional I/R injury (Fig. 5). I/R induced a significant 
increase in the plasma level of TNF-α after 6 h reperfusion. The 
elevation of plasma TNF-α in the I/R + NS group (18 ± 1.2 ng/
ml) was significantly greater than the I/R + U50 (16 ± 0.9 ng/
ml, P = 0.042) and I/R + U100 (13 ± 0.6 ng/ml, P < 0.001) groups 
after regional I/R injury (Fig. 6). 
Discussion
Myocardial I/R injury is a major event in many clinical situ-
ations including the perioperative period, coronary throm  bolysis, 
percutaneous coronary intervention, coronary artery bypass 
graft, and cardiac transplantation [16-18]. The non-cardiac 
surgical patient at risk of myocardial I/R injury is growing 
because of perioperative morbidity and mortality [16,17]. In this 
situation, applying the appropriate agents to reduce myocardial 
Fig. 1. Comparison of hemodynamic function in the I/R + NS, I/R + U50, and I/R + U100 groups. Values are means ± SD (n = 10/group). The 
I/R + NS group - rats in which 1 ml of NS was administered intraperitoneally 30 min before the ischemic insult; I/R + U50 group - rats in which 
50,000 U/kg of ulinastatin diluted with NS was administrated intraperitoneally 30 min before the ischemic insult; I/R + U100 - rats in which 
100,000 U/kg of ulinastatin diluted with NS was administered intraperitoneally 30 min before the ischemic insult. HR, heart rate; LVEDP, left 
ventricular end diastolic pressure; I/R, ischemia/reperfusion; NS, normal saline. R0.5, 30 min after reperfusion; R1, 1 h after reperfusion; R1.5, 
1 h 30 min after reperfusion; R2, 2 h after reperfusion; R6, 6 h after reperfusion. *P < 0.05 compared to basal hemodynamic function in the I/R 
+ NS group. 
†P < 0.05 compared to the I/R + NS group. 
‡P < 0.05 compared to the I/R + U50 group.503 www.ekja.org
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I/R injury is critical. Thus, considerable research has been made 
to determine means to protect against myocardial injury. This 
study describes the benefit of ulinastatin as a myocardial pro-
tective agent. 
Ulinastatin improved myocardial contractility, reduced 
myocardial infarct size, and decreased serum levels of CK and 
cTnI after regional I/R injury in an in vivo rat heart model. This 
pro  tection appears to be, at least in part, due to inhibition of 
TNF-α and MPO activities, which are indexes of tissue neutro-
phil infiltration and activation.
Myocardial infarction causes neutrophil infiltration into the 
infarct zone and increases the production of pro-inflammatory 
cytokines such as TNF-α [19-21]. Accumulation of neutrophils 
is evidence of acute inflammation and the infiltration of 
neutrophil can initiates myocardial damage [19,20]. The MPO 
activity assay is widely used to a biomarker for neutrophil 
infiltration and inflammatory reactivity, as MPO is an enzyme 
that is released mainly from neutrophils. Considering the 
attenuated MPO activity in the present study, ulinastatin 
may exert a myocardial protective effect by inhibiting the 
inflammatory process. 
A previous study showed that ulinastatin has anti-inflamma-
tory and organ protective effects in various I/R injury models 
[4,7-13]. Especially, ulinastatin has a myocardial protective 
effect by various mechanisms in an in vivo rat heart model. In 
reperfusion after hemorrhagic shock, ulinastatin contributed to 
the recovery of cardiac function after reperfusion by reducing 
the severity of mitochondrial dysfunction and maintaining 
energy production [6]. Ulinastatin also improved functional 
recovery of the heart after long cardioplegic arrest in an in 
vitro rabbit heart model [7]. In this study, ulinastatin had a 
myocardial protective effect via an anti-inflammatory response. 
Our study also showed that ulinastatin had a myocardial 
protective effect in the regional I/R injury in an in vivo rat heart 
Fig. 2. Comparison of myocardial infarct size in the I/R + NS, I/R + 
U50, and I/R + U100 groups. Values are means ± SD (n = 10/group). 
The I/R + NS group - rats in which 1 ml NS was administered 
intraperitoneally 30 min before the ischemic insult; I/R + U50 
group - rats in which 50,000 U/kg ulinastatin diluted with NS was 
administrated intraperitoneally 30 min before the ischemic insult; 
I/R + U100 - rats in which 100,000 U/kg ulinastatin diluted with 
NS was administered intraperitoneally 30 min before the ischemic 
insult. AAR, area at risk; LV, left ventricle; IA, infracted area; I/R, 
ischemia/reperfusion; NS, normal saline. *P < 0.05 compared to the 
I/R + NS group.
Fig. 3. Serum levels of creatine kinase at 6 h post-reperfusion. Values are 
means ± SD (n = 6/group). The I/R + NS group - rats in which 1 ml 
NS was administered intraperitoneally 30 min before the ischemic 
insult; I/R + U50 group - rats in which 50,000 U/kg ulinastatin 
diluted with NS was administrated intraperitoneally 30 min before 
the ischemic insult; I/R + U100 - rats in which 100,000 U/kg ulina-
statin diluted with NS was administered intraperitoneally 30 min 
before the ischemic insult. CK, creatine kinase; I/R, ischemia/reper-
fusion; NS, normal saline. *P < 0.05 compared to the I/R + NS group. 
†P < 0.05 compared to the I/R + U50 group.
Fig. 4. Serum levels of cTnI at 6 h post-reperfusion. Values are means 
± SD (n = 6/group). Sham + NS group - rats in which 1 ml of NS was 
administered intraperitoneally 30 min before operation without 
tight  ening of the left coronary artery; sham + U100 - rats in which 
100,000 U/kg of ulinastatin diluted with NS was administered 
intraperitoneally 30 min before operation without tightening of the 
left coronary artery; I/R + NS - rats in which 1 ml of NS was admini-
stered intraperitoneally 30 min before the ischemic insult; I/R + U50 
group - rats in which 50,000 U/kg of ulinastatin diluted with NS was 
administrated intraperitoneally 30 min before the ischemic insult; 
I/R + U100 - rats in which 100,000 U/kg of ulinastatin diluted with 
NS was administered intraperitoneally 30 min before the ischemic 
insult. cTnI, cardiac troponin-I; I/R, ischemia/reperfusion; NS, 
normal saline. *P < 0.05 compared to the I/R + NS group.504 www.ekja.org
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model. 
Measurements of endogenous mediator, TNF-α, allowed to 
elucidate the inflammatory response pathway. TNF-α is a potent 
pro-inflammatory cytokine that acts on vascular endothelial 
cells to induce expression of leukocyte adhesion molecules 
[20,22]. TNF-α is upregulated in the myocardium in response 
to a variety of cardiac injuries, including transient myocardial 
ischemia and reperfusion [22]. This suggests the possibility 
that TNF-α plays an important role in vivo in the pathogenesis 
of post-ischemic myocardial inflammation and I/R injury. 
In the present study, the significant reduction of TNF-α after 
ulinastatin suggests ulinastatin’s possible myocardial protective 
effect via the inhibition of pro-inflammatory cytokine release. 
Taken together, our results suggest that an anti-inflammatory 
effect is an important mechanism for myocardial protection 
following regional I/R injury in an in vivo rat heart ischemia 
model. The dose of ulinastatin was higher compared with 
clinically relevant doses. In this experiment, we used 50,000 
and 100,000 U/kg of ulinastatinn because these dosages had an 
organ protective effect in previous studies [ 6,9,10 ]. 
Our study has some limitations. First, necrotic cell death 
reaches a peak at 24 h after I/R injury, whereas apoptotic cell death 
develops progressively until 72 h [23]. This study observed the 
myocardial protective effects after 6 h of reperfusion. Therefore, 
long-term observations will be needed to determine whether 
the effect is temporary or sustained. Second, ulinastatin was 
administered intraperitoneally and lacked a docu  mented 
serum drug level. Therefore, this study cannot confirm that a 
clinically relevant ulinastatin concentration was associated with 
a myocardial protective effect.
In conclusion, ulinastatin reduced cardiac dysfunction, 
infarct size, MPO activity, and TNF-α release after regional I/R 
injury in an in vivo rat heart model. Its protective effect may be 
attributable to its anti-inflammatory. 
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